Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tharimmune, Inc. - Common Stock (NQ:THAR)

1.260 -0.040 (-3.08%)
Streaming Delayed Price Updated: 10:12 AM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,592
Open 1.260
Bid (Size) 1.250 (2)
Ask (Size) 1.280 (7)
Prev. Close 1.300
Today's Range 1.255 - 1.260
52wk Range 0.9520 - 6.390
Shares Outstanding 4,635,251
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl
Via ACCESS Newswire

Performance

YTD
-38.5%
-38.5%
1 Month
-24.3%
-24.3%
3 Month
-12.1%
-12.1%
6 Month
-33.3%
-33.3%
1 Year
-55.6%
-55.6%

More News

Read More
Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
Via ACCESS Newswire
Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery
Via ACCESS Newswire
Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants
Via ACCESS Newswire
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors
Via ACCESS Newswire
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Via ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
Via ACCESS Newswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
Via ACCESS Newswire
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
Via ACCESS Newswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Via ACCESS Newswire
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
Via ACCESS Newswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Via ACCESS Newswire
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Via ACCESS Newswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Via ACCESS Newswire
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Via ACCESS Newswire
Tharimmune to Present at the Microcap Conference 2025
Via ACCESS Newswire
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Via ACCESSWIRE
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
Via ACCESSWIRE
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Via ACCESSWIRE

Frequently Asked Questions

Is Tharimmune, Inc. - Common Stock publicly traded?
Yes, Tharimmune, Inc. - Common Stock is publicly traded.
What exchange does Tharimmune, Inc. - Common Stock trade on?
Tharimmune, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tharimmune, Inc. - Common Stock?
The ticker symbol for Tharimmune, Inc. - Common Stock is THAR on the Nasdaq Stock Market
What is the current price of Tharimmune, Inc. - Common Stock?
The current price of Tharimmune, Inc. - Common Stock is 1.260
When was Tharimmune, Inc. - Common Stock last traded?
The last trade of Tharimmune, Inc. - Common Stock was at 08/19/25 10:12 AM ET
What is the market capitalization of Tharimmune, Inc. - Common Stock?
The market capitalization of Tharimmune, Inc. - Common Stock is 5.84M
How many shares of Tharimmune, Inc. - Common Stock are outstanding?
Tharimmune, Inc. - Common Stock has 6M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.